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Hypertension continues to be a major risk factor for global mortality, and recent genome-wide 
association studies (GWAS) have expanded in size, leading to the identification of further genetic loci 
influencing blood pressure. In light of the new knowledge from the largest cardiovascular GWAS to 
date, we review the potential impact of genomics on discovering potential drug targets, risk 
stratification with genetic risk scores, drug selection with pharmacogenetics, and exploring insights 
provided by gene-environment interactions. 
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Introduction  
Hypertension continues to be a major cause of worldwide mortality and morbidity (1), with genomics 
proposed to have the potential to assist in reducing the overall burden of cardiovascular events (2). 
The role of genomics has stretched from the initial discovery of monogeneic diseases with large effects 
(3), to large-population genome-wide association studies (GWAS) detecting common genetic 
variations with modest effect sizes. The recent publication of the largest cardiovascular genetic 
association study to date, with over 1 million participants, demonstrated the total number of genetic 
signals associated with hypertension surpassing 1000, at 901 genetic loci (4). Each subsequent GWAS 
iteration continues to increase our understanding of the genetic architecture of hypertension and 
cardiovascular disease. Here, we review the promise of translating genomics into clinical application 
through potential novel treatment options, risk scores, gene-environment interactions, or 
pharmacogenetics.  
 
Blood pressure genomics 
The vast information provided by large GWAS has resulted in greater understanding of the polygenic 
nature of blood pressure regulation, where numerous single nucleotide polymorphisms (SNPs) act 
additively to impact on cardiovascular disease. However, the translation into establishing the 
underlying genetic mechanism remains difficult. The key barrier is that the causal variant might not 
be readily identified by the lead GWAS SNP. Instead, the lead SNP indicates a chromosomal region 
where the causal gene may typically reside within a 500kb genetic window, with other SNPs in high 
linkage disequilibrium (LD) (5). This window however only serves as broad guidance, with the 
increasing understanding of the 3-dimensional configuration of DNA as being important to genetic 
function, particularly with the discovery of various genomic regions with high levels of local chromatin 
interactions implicating longer-range interactions (6). Chromatin interaction Hi-C studies aim to 
identify long-range target genes of non-coding SNPs, and the recent blood pressure GWAS has 
identified up to 484 long-range interactions, for example between the SLC30A10 locus and the TGFB2 
gene being 1.2Mb apart (4). To compound this complexity, the potential for trans-acting regulatory 
elements (7) makes identifying the functional variant difficult to pinpoint. Furthermore, a significant 
proportion of GWAS-significant SNPs is intergenic or near genes without any obvious connection to 
cardiovascular disease.  
 
To date, there has been some success in exploring the functional impact of these genetic variants.  
Perhaps the best example remains the UMOD (uromodulin) gene where the 5’ SNP rs13333226 was 
identified as associated with hypertension in an early GWAS (8). Subsequently, UMOD-deficient mice 
demonstrated increased sequestration of the loop diuretic target sodium-potassium-chloride co-
transporter 2 (NKCC2) in subapical vesicles together with reduced phosphorylation, both combining 
with resultant reduced co-transporter activity (9). Mimicking the effect of loop diuretics, this resulted 
in increased natriuresis and a 20 mmHg lower blood pressure in knockout mice. The BP difference 
was exacerbated with salt-loading, where the knockout mice were resistant to its hypertensive effects 
(10). Conversely, the blood pressure of UMOD transgenic mice were salt-sensitive (11).  
 
More recent successes include exploring the genetic function of blood pressure loci, including NPR3 
(12), SLC4A7 (13) and SLC39A8 (14). The BP-raising allele at the NPR3 (Natriuretic peptide receptor C) 
locus was associated with altered chromatin interactions, increased NPR3 expression, linked to 
increased vascular smooth muscle cell proliferation, angiotensin II-induced calcium flux and cell 
contraction (12). Vascular smooth muscle has also been shown to be relevant to the SLC4A7 
(electroneutral sodium-bicarbonate cotransporter 1) locus. The BP-raising allele was associated 
altered chromatin interactions, increased gene expression, elevated steady-state intracellular pH and 
accelerated recovery from intracellular acidosis, all independent of the missense polymorphism 
resulting in the amino acid substitution Glu326Lys (13). Vascular endothelial cells appear to have a 
greater influence with the SLC39A8 locus, encoding ZIP8, a heavy metal ion transporter. The blood 
pressure polymorphism is associated with an Ala391Thr variation where blood pressure raising 
variant Ala391 demonstrated a higher propensity to cadmium accumulation, increased ERK2 
phosphorylation, NFkB activation, and reduced vascular endothelial cell viability (14). 
 
With the increased number of genetic loci identified, experimental exploration of each individual 
locus becomes unfeasible. Despite these complexities, there is still hope that future therapeutic 
targets could be identified within these genetic loci. There has been a rapid expansion of 
bioinformatics tools that can assist in prioritising areas to optimise the use of resources to identify 
new therapeutic options. The process of investigating genetic variants can be assisted by in silico 
analysis, indicating loci with eQTLs in tissues of interest (e.g. GTEx, www.gtexportal.org), DNase I 
hypersensitivity sites (e.g. DeepSEA, http://deepsea.princeton.edu/), as well as a handful of non-
synonymous polymorphisms that have been predicted to be damaging (e.g. SIFT, http://sift.jcvi.org/; 
and PolyPhen, http://genetics.bwh.harvard.edu/pph2/). Druggability analyses have provided new 
genetic support for known anti-hypertensive targets (4), with genetic loci including targets of 
established antihypertensive medications such as SLC12A2 (loop diuretics), CACNA1C and CACNB4 
(calcium channel blockers), within the pathway itself such as NOS3 (nitric oxide donors), targets under 
investigation EDN1 (endothelin 1), NPR1 and NPR3 (natriuretic peptide analogues), and ENPEP 
(aminopeptidase A inhibitors), or drugs with known antihypertensive effects that could allow for 
repurposing such as SLC5A1 (sodium-glucose co-transporter 2 inhibitors for diabetes mellitus). This 
demonstrates, as a proof of concept, the capabilities of genetic studies. In other words, the ability to 
confirm genetic associations for genes that are the targets of current anti-hypertensive drug targets, 
then it provides hope that some of the other newly discovered genes for blood pressure may also 
have the potential to lead to new and improved drugs for hypertension in the future.  
 
In silico functional analyses on gene expression have also highlighted the enrichment of genes relating 
most strongly to the vasculature, and to a lesser extent, adrenal and adipose tissue. From pathway 
analyses, there was also an enrichment of signals within the transforming growth factor-β (TGFβ) 
pathway (4), which is a pathway known to influence renal sodium handling and ventricular 
remodelling. Furthermore, plasma TGFβ levels have been correlated with hypertension (15). The 
genes implicated include the growth factor itself (TGFB2), its receptors (TRFBR2 and TGFBR3), 
downstream signalling proteins such as the activin A receptor type 1C (ACVR1C) and bone 
morphogenetic protein 2 (BMP2), and transcription factors important in TGFβ signalling, such as 
Kruppel-like family 14 (KLF14) which regulates expression of TGFβ receptors (16). This might suggest 
members of this pathway as future novel therapeutic targets. 
 
In recent years, there has also been an increased interest in epigenomic-wide association studies 
(EWAS). Analogous to GWAS utilising SNPs, these studies utilise quantifiable epigenetic marks, 
typically DNA methylation, to identify loci that can discriminate between cases and controls (17). 
EWAS, combined with gene expression analyses have identified six genes (TSPAN2, SLC7A11, 
UNC93B1, CPT1A, PTMS, and LPCAT3) with mutual associations between methylation, gene 
expression, and blood pressure. These genes have hitherto not been implicated in the pathogenesis 
of hypertension with GWAS, indicating a distinct and cumulative gain of knowledge with from this 
complementary methodology (18). Like its genomic counterpart, EWAS too has limitations. Epigenetic 
variations may arise as either a cause or a consequence of disease, and can be difficult to differentiate 
without the use of expensive and time-consuming longitudinal cohort studies. In addition, samples 
currently utilised for EWAS for are almost invariably blood, which may not reflect the unique 
epigenetic signature of the tissue of interest.  
 
Genomics of blood pressure and other cardiovascular risk factors 
In terms of prioritising research for potential future therapies, it may be reasonable to consider 
genetic loci that are signals across other cardiovascular risk factors in addition to hypertension, which 
often co-exist (Table 1)(4, 19-24). These signals of interest include BCL2 (B-Cell CLL/Lymphoma 2), 
CPS1 (Carbamoyl-Phosphate Synthase 1) and MTNR1B (Melatonin Receptor 1B). The 
rs79598313/KDF1 (Keratinocyte Differentiation Factor 1) locus is more complex as the genes within 
this LD block also includes ARID1A (AT-Rich Interaction Domain 1A), NUDC (Nuclear Distribution C, 
Dynein Complex Regulator) and ZDHHC18 (Zinc Finger DHHC-Type Containing 18), where little is 
known of these gene products in relation to pathogenesis of hypertension. As there is a large body of 
evidence already on APOE in cardiovascular research, this locus is not reviewed in detail here. 
 
BCL2 is a known inhibitor of apoptosis (25), and is positioned within the angiotensin II-induced 
endothelial apoptosis pathway (26). However, it is unclear whether modulating BCL2 function has an 
impact on endothelial survival or function. BCL2 also has a role in a range of tissues, and its 
upregulation in numerous tumours has made it a potential cancer therapeutic target (27). With this, 
there is potential for off-target effects and may give reason to pause if considering BCL2 as an anti-
hypertensive/diabetic therapy.  
 
Carbamoyl-phosphate synthase 1 (CPS1) catalyses the rate-limiting step in the urea cycle and L-
citrulline production. Vascular endothelial cells synthesize endogenous L-arginine by recycling L-
citrulline, the by-product of nitric oxide synthesis, using components of the urea cycle, potentially 
linking nitric oxide production and the urea cycle. There is already some support for CPS1 as a 
regulator of vascular tone, where the naturally occurring T1405N variation has been observed to 
influence forearm blood flow responses to bradykinin and nitroprusside, and levels of nitric oxide 
metabolites (28). There is less known about the biological link between CPS1 and HDL cholesterol, 
except that there the proteomic changes in murine adipose tissue following a high fat diet were 
primarily within the urea cycle, including CPS1 (29). There may be however concerns for off-target 
effects when modulating CPS1 activity. Expression data from GTEx suggests that CPS1 is 
predominantly expressed in the liver. Furthermore, CPS1 deficiency is a rare autosomal recessive 
inherited disease resulting in severe hyperammonaemia and protein intolerance (30).  
 
MTNR1B encodes a high affinity receptor for melatonin (31), and appears to influence 24-hour non-
rapid eye movement sleep (32). There is some epidemiological support for the influence of melatonin 
on circadian blood pressure (33), and melatonin reducing nocturnal BP in a small clinical trial (34). This 
discovery of a melatonin receptor as a genetic signal for blood pressure may provide further impetus 
to revisit melatonin as a therapeutic target. There is a larger body of evidence for MTNR1B in type II 
diabetes mellitus in terms of genetic/genomic analyses, clinical/epidemiology data, functional 
analyses of genetic polymorphisms, in vitro and animal model, where there are still controversies on 
the potential relationship (35). 
 
Genomics of blood pressure and other cardiovascular endpoints 
An alternative aid prioritising genetic loci to undergo functional assessment would consider those that 
overlap with the genetic signals of cardiovascular endpoints. This approach is however limited by the 
heterogeneous pathophysiology of cardiovascular endpoints, particularly with heart failure, stroke 
and chronic renal disease (Table 2)(24, 36-41). Furthermore, there is notable variation in classification 
of phenotypes within each cardiovascular endpoint (e.g., chronic kidney disease has also been 
investigated under phenotype classifications of end-stage renal failure, creatinine and kidney function 
decline). Another limitation is the lower prevalence of heart failure and stroke, and subsequently, a 
limited number of large GWAS.  
 
Signals of association that overlap between blood pressure and coronary artery disease GWAS include 
APOE (Apolipoprotein E), EDNRA (Endothelin Receptor Type A) and SWAP70 (SWAP Switching B-Cell 
Complex Subunit 70). Overlapping GWAS signals for blood pressure and renal function include VEGFA 
(Vascular Endothelial Growth Factor A) and the aforementioned CPS1 (Carbamoyl-Phosphate 
Synthase 1) (Table 3)(4, 37, 38, 40, 42, 43).  The impact of apolipoprotein E and endothelin on 
cardiovascular disease has been well described and not discussed further in this review.  
 
SWAP70 belongs to a family of proteins involved in an array of processes that control autoimmune 
phenotypes which spontaneously develop in their absence (44), where one of its homologues is 
associated with the development of systemic lupus erythematosus (SLE) (45). Autoimmune diseases 
are increasingly recognised as a risk factor for cardiovascular disease, with the latest cardiovascular 
risk calculator, QRISK3, having added SLE into the latest iteration (46). Most of the studies on SWAP70 
thus far centre on immune cells. However, in context of Kaposi sarcomas, SWAP70 was found to be 
crucial for in vitro endothelial tube formation and endothelial sprouting (47). The relevance of this 
finding to endothelial cells in blood pressure regulation is unclear.  
 
The presence of VEGFA on this list is not surprising due to the side effect profile of anti-VEGF cancer 
therapies with increased risk of hypertension, proteinuria and myocardial infarctions (48, 49). The 
proposed mechanism would be via both vascular and renal endothelial cells, and podocytes. Reduced 
VEGF activity in the vascular endothelium could lead to vascular rarefaction and reduced nitric oxide 
availability. Within the kidneys, there could also be downregulation of tight junctions, resulting in 
proteinuria (48). The importance and opposing effect of VEGF in cancer pathways suggests that it is 
less likely to be a successful candidate target for cardiovascular disease. 
 
It is also notable that the ABO gene (α-1,3-N-Acetylgalactosaminyltransferase And α-1,3-
Galactosyltransferase), most commonly known for its influence on the ABO blood group, is a signal 
across multiple traits, including blood pressure (4), glycated haemoglobin A1c (50), 
hypercholesterolaemia (51), and ischaemic heart disease (52), but with various SNPs not in high LD. 
The ABO blood group has long been an established risk factor for arterial thrombosis (53), and a recent 
meta-analysis, the clinical phenotype of ABO blood group itself is a risk factor for coronary artery 
disease, where blood group A carried the highest risk, and lowest risk with blood group O (54). This 
may be in part related to the presence of N-linked oligosaccharide side chains on von Willebrand 
factor (vWF) molecules that contain A and B blood group antigens which in turn decreases von 
Willebrand factor clearance (55). Individuals with non-O (A, B, or AB) blood groups have 25% higher 
vWF levels than individuals with blood group O (56). There may also be a role for angiotensin 
converting enzyme in this relationship between ABO and cardiovascular disease. Both the ABO 
genotype (57, 58) and blood group phenotype (59) are associated with angiotensin-converting 
enzyme activity. This may in part provide the biological link with hypertension. The relationship 
between the ABO locus and type II diabetes and hypercholesterolaemia may lie with the link with 
pancreatic lipase levels varying with ABO genotype at GWAS-significance levels (57), but this 
hypothesis still requires further study. Overall, this may suggest that α-1,3-N-
acetylgalactosaminyltransferase or α-1,3-galactosyltransferase may be a possible therapeutic target, 
spanning multiple cardiovascular comorbidities. 
 
Genetic risk scores  
Outside of generating new pharmacological targets, a different route that genomics can potentially 
influence clinical care is via augmenting the predictive value of clinical risk scores. Clinical risk scores 
have long been in use to estimate the actual risk of developing a disease of a defined population, and 
that the absolute risk of cardiovascular disease is influenced by the combination of risk factors (60, 
61). Likewise, even though each blood pressure-associated variant only has a small effect individually, 
a genetic risk score (GRS) can consider the larger aggregated effects of all combined variants. Clinical 
interventions (both pharmacological and lifestyle) can be effective in delaying the disease progression 
from prehypertension to hypertension, and the development of cardiovascular events, but also carries 
the risk of adverse events, as well as financial and opportunity costs. With this, improvements in 
prediction models to stratify patient populations according to risk would allow a precision medicines 
strategy to prevent future cardiovascular disease. Genetic risk scores aim to add to clinical risk scores 
to enhance its predictive value. 
 
The combination of the all known BP variants across 901 loci was associated with a 10.4 mmHg higher 
SBP, and an over three-fold sex-adjusted higher risk of hypertension (OR 3.34), and odds ratio of 
incident cardiovascular events of 1.52 comparing top-bottom GRS deciles (4). This predictive ability 
of GRS highlights the potential to influence clinical management by improved risk stratification. 
However, this does not assess the utility of GRS in addition to current clinical risk scores. A study using 
only 22 blood pressure variants as part of a genetic risk score improved discrimination for incident 
hypertension on top of clinical risk factors, but only modestly (C-index change = 0.3%–0.5%) (62). 
While this only showed a modest change, it only utilised a small fraction of known loci and there is 
potential to improve the discriminatory power by using all the 901 known loci.  
 
To assess the impact of genetics and exposure to lifestyle factors on blood pressure, a genetic risk 
score composed of 314 blood pressure loci was assessed together with a healthy lifestyle score (BMI, 
sedentary hours, alcohol intake, meat intake, urinary sodium excretion, fruit and vegetable intake, 
fish intake and smoking status). For all genetic risk score tertiles, a healthier lifestyle score is 
associated with lower blood pressure and improved outcomes (63). A separate study focused on the 
impact of genetic influence on salt-sensitivity with participants undertaking specific dietary 
interventions of low-sodium, high-sodium and high-sodium/potassium-supplemented diets. Higher 
GRS conferred larger rises in blood pressure when exposed to a high-sodium diet, but a smaller blood 
pressure fall with a low-sodium diet. However, the overall influence of the GRS groups is far smaller 
than that of the dietary interventions itself (64). Taken together, this emphasises that lifestyle 
management should be for the whole population, rather than targeted using genetic information. 
 
There may however be utility for GRS within a “precision medicine” approach. An example could be 
seen in studies where GRS improved clinical risk score C-statistics of predictive coronary artery disease 
in the region of 0.4 to 1% (65, 66), utilising between 20 to 50 SNPs in these GRS. Importantly, this 
small SNP panel resulted in net reclassification by 5 to 9% (66). The improved reclassification to 
influence the decision to initiate treatment with statins has numbers-needed-to-treat (NNTs) in the 
ranging between 20s and 60s, being lower for those with the highest genetic risk (66, 67). GRS has 
also been proposed as a potential motivator in adherence to lifelong pharmacological therapies and 
behavioural changes, particularly in use for counselling patients with those at higher risk categories. 
Adding GRS to standard-of-care in counselling patients with coronary artery disease may produce 
some benefits in changing behaviours. In randomised controlled trials, the additional knowledge of 
their GRS resulted in modest weight loss and increased physical activity (68), and improvements in 
LDL-cholesterol (69), but requires further evaluation particularly to consider whether it impacts on 
clinical end-points. This added GRS-based counselling could be important in translating into 
management of patients with resistant hypertension, where non-adherence to medications is known 
to be high (70). 
 
There is however other barriers before GRS reach clinical practice. While there may be some clinical 
benefit from GRS, it is well worth considering the cost implications of genotyping arrays, particularly 
as it would involve a large screening population, and in view of the potentially large NNTs. There 
should also be consideration of the potential ethical impact of such risk scoring and the potential to 
impact on day-to-day lives of the general population receiving genetic risk score results. At the time 
of this review, several countries have chosen not to adopt laws to specifically prohibit access to 
genetic data for purposes of life insurance. Several other countries have either adopted laws or 
developed voluntary moratoria with the industry to prevent this access (71). The impact would be 
regional, particularly as the perceptions and importance of life insurance varies from country-to-
country, and within countries itself. There would also be the cost implications of providing the 
necessary counselling that should be provided together with such results.  
 
Hypertension gene-environment (GxE) interaction studies 
Another method of elucidating the impact of genetics on the pathogenesis of hypertension is through 
gene-environment (GxE) interaction studies. The model of GxE studies is based on the hypothesis that 
individuals may be more vulnerable to the negative effects of environmental adversity, or 
alternatively, more responsive to positive environmental experiences. GxE studies can also reveal 
further blood pressure-associated loci that can only be detected via an adjustment of, or interaction 
with, environmental exposure.  
 
A productive region of GxE research thus far is with salt-sensitivity, where the GenSalt consortium 
identified up to 9 genetic loci interacting with dietary salt intake to influence blood pressure (72). 
Potential therapeutic targets that may arise from these findings is from the CASP4 (Caspase 4) and 
MNK1 (MAP Kinase Interacting Serine/Threonine Kinase 1) loci. Caspase 4 is a protein in the cysteine-
aspartic acid protease family that plays an import role in inflammation and innate immunity. The loss 
of proximal tubules and renal injury in nephropathic cystinosis appears to be associated with 
overexpression of the CASP4 gene (73). In view of the importance of renal sodium filtration and 
reabsorption, further studies on the potential role of CASP4 in salt-sensitivity may be warranted. MAP 
Kinase Interacting Serine/Threonine Kinase 1 (MNK1 gene) functions as a Ser/Thr protein kinase that 
interacts with ERK1 and p38 mitogen-activated protein kinase (MAPK) (74), a pathway that is involved 
in BP regulation through norepinephrine and angiotensin II (75). Its pathophysiological role in salt-
sensitivity is unclear, but due to its position in a known blood pressure regulating pathway, may be an 
area of fruitful investigation. 
 
Other gene-environment interactions for blood pressure identified so far include 15 genetic loci 
identified to interact with cigarette smoking to influence blood pressure (76). Additionally, SLC16A9 
(Solute Carrier Family 16 Member 9, also known as Monocarboxylic Acid Transporter 9) interacting 
with alcohol consumption (77), and TMEM182 (Transmembrane Protein 182) with body-mass index 
(78), where the biological relevance for both findings are currently uncertain. 
 
Hypertension pharmacogenetics 
Worldwide, optimal blood pressure management is achieved in fewer than 40% of those treated, 
despite the availability of a considerable number of drugs from different pharmacological classes (79). 
Although there are numerous contributing factors for this, one is the degree of genetic-based inter-
subject variation in response to different pharmacological classes. Pharmacogenomics have been 
proposed to have the potential to identify genetic signals that could predict therapeutic effect or 
adverse outcomes for different drug classes (80). Currently, decisions on antihypertensive drug 
therapy selection may be based on age and ancestry (81-83), which in turn acts as a surrogate for 
plasma renin activity (84). It remains that any use of pharmacogenetics requires an increase in 
predictive value in addition to current clinical stratification. 
 
While candidate gene studies are not particularly common in the current era of genome-wide studies, 
one of the strongest evidence for pharmacogenetics relates to the genetic locus at ADRB1 (𝛽1-
adrenoceptor) and the blood pressure response to 𝛽-blockers (85), which has also since been shown 
to impact on heart failure outcomes (86). As only very few genetic variants yielded pharmacogenetics 
effects individually, risk score models combining the effects of multiple polymorphisms have been 
investigated. For example, within the Pharmacogenomic Evaluation of Antihypertensive Responses 
(PEAR) study, using a risk score including SNPs within the FGF5, CHIC2, MOV10, and HFE genes, reveals 
a potential difference in response to 𝛽-blockers in the magnitude of 14/20 mmHg (p=3.3x10-6 for SBP; 
p=1.6x10-6 for DBP) comparing carriers of one vs. six risk alleles (87).  
 
Another candidate gene study was based on the knowledge renal tubular expression of epithelial Na+-
channel (ENaC) which is known to be influenced by a functional NEDD4L (Neural Precursor Cell 
Expressed, Developmentally Down-Regulated 4-Like, E3 Ubiquitin Protein Ligase) polymorphism. A 
subset of the NORDIL (Nordic Diltiazem) trial revealed a pharmacogenetics effect at rs4149601, where 
carriers of the variant associated with higher ENaC expression had a greater reduction in blood 
pressure for patients taking β-blocker or diuretic monotherapy but not the calcium channel blocker 
diltiazem (88). The genetic effect (around 4.5/1.5 mmHg) is, however, modest compared the overall 
therapeutic effect of these medications (around 15-19/14-15 mmHg), and there is no clear indication 
that knowledge of the genotype can influence drug choice in a clinically significant manner.  
 
The exploration of pharmacogenetics of antihypertensive therapies has since reached the GWAS era. 
Thus far, pharmacogenetics influences on the efficacy of a diuretic (hydrochlorothiazide) have been 
shown with variants at the LYZ-FRS2-YEATS4 (Bonferroni corrected P=0.024) (89), PRKCA (p=3.3×10-8) 
(90) loci with allelic effects within the region of 3-8/2-4 mmHg, with the GNAS-EDN3 locus approaching 
genome-wide significance (p=5.5×10-8) (90). Both PRKCA (Protein kinase Cα) and GNAS-EDN3 (GNAS 
Complex Locus and endothelin 3, respectively) loci encode proteins involved in calcium signalling and 
vascular smooth muscle contraction, but the potential biological relevance of LYZ (Lysozyme), FRS2 
(Fibroblast Growth Factor Receptor Substrate 2) or YEATS4 (YEATS Domain Containing 4) is currently 
unclear. There has also been a reported pharmacogenetic impact of the SLC25A31 rs201279313 
deletion genotype influencing blood pressure response to β-blockers in a study limited to African 
Americans (p=2.5×10-8), with the LRRC15 locus approaching genome-wide significance (p=7.2×10-8). 
The relevance of both these genes in the blood pressure regulation or the 
pharmacokinetics/pharmacodynamics of β-blockers is unclear (91). However, as these studies only 
assessed the response to one drug class, it would not assist in decision making between different the 
use of different therapeutic drug classes. A following Genetic Epidemiology of Responses to 
Antihypertensives (GERA) study aim to identify SNPs with pharmacogenetic effects exhibiting opposite 
direction associations with BP response between diuretic and angiotensin II receptor blocker 
treatments, but the results were not replicated in an independent study, with none of the SNPs 
attained genome-wide significance (92). A pharmacogenetics GWAS study randomly allocating 
patients to bisoprolol, losartan, HCTZ or amlodipine as monotherapy in a cross-over design initially 
demonstrated three SNPs (at the ACY3 gene) were significantly associated to BP response to 
bisoprolol, but none were successfully replicated (93). 
 
Adverse drug reactions has a role in medicines non-adherence, which in turn contributes to 
suboptimal blood pressure management. Therefore, the ability to predict the likelihood of adverse 
drug events may be useful. The ACE inhibitor-induced cough is common, and often necessitates a 
change in drug class to an angiotensin receptor blocker. This adverse effect has been shown in 
variations in ABO haplotype (94, 95), SLCO1B1 (96), KCNIP4 (97), BDKRB2 (94), NK2R (98) and the ACE 
insertion/deletion variant (99), although these variants were not detected in a recent 
pharmacogenetics GWAS (100). Thiazide-induced hyponatraemia is also common and can have severe 
consequences. This adverse reaction has been recently shown to be associated with 14 genetic 
regions, with further testing indicating a non-synonymous variation of SLCO2A1 (Solute Carrier 
Organic Anion Transporter Family Member 2A1, also known as Prostaglandin Transporter), also 
showing a phenotype of intravascular volume expansion, free water reabsorption, urinary 
prostaglandin E2 excretion, and reduced excretion of serum chloride and antidiuretic hormone (101). 
Pharmacogenetic GWAS have also identified up to 6 genetic signals for hydrocholorothiazide-induced 
hyperuricaemia (102). 
 
Despite these advances, pharmacogenetics in hypertension is still far from clinical practice, and 
requires comparison against successes elsewhere. Pharmacogenetics of predicting adverse drug 
events has had success with HLA-B*5701 screening for hypersensitivity to the anti-HIV-therapy, 
abacavir, where there is high predictive value and the ability to prevent a severe, life-threatening 
reaction (103). This has perhaps set an exceedingly high standard of impact that a pharmacogenetic 
test for adverse drug reactions should achieve. The antihypertensive pharmacogenetic studies thus 
far have only provided some mechanistical insights, but without the necessary predictive values and 
to influence the choice of antihypertensive drugs. 
 
Our current understanding of pharmacogenetics is often complicated by datasets that includes 
polypharmacy (including non-cardiovascular medications), numerous drugs and dosing ranges within 
each antihypertensive drug class, resulting in multiple confounding factors. To minimise these 
confounders, most pharmacogenetic GWAS so far have used subsets of randomized controlled trials 
comparing different classes of antihypertensive drugs, for which consenting subjects have 
subsequently been genotyped, for example the GenHAT study as a subset of the ALLHAT study (104). 
Furthermore, studies in pharmacogenetics still lag behind the large sample sizes of GWAS. In the 
context of clinically-predetermined guidelines for first-line (and even second- and third-line) drug 
choices (83), it may be difficult to obtain sufficient new data that would be able to compare 
pharmacogenetic effects. With this, the International Consortium for Antihypertensive 
Pharmacogenomics Studies (ICAPS) was formed in 2012 to increase the opportunities to discover and 
replicate genetic signatures of many different phenotypes related to antihypertensive treatment 
response. To date, no signals reach genome-wide significance for influencing the impact of diuretics 
on blood pressure (105). Alternatively, consortia such as the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) Consortium (http://www.chargeconsortium.com) have included 
observational studies within pharmacogenetics analyses, using longitudinal cohorts containing 
accurate medical records for drug exposure. Similarly, this has so far been unable to identify any 
genome-wide significant interactions from four antihypertensive therapy meta-analyses for 
cardiovascular outcomes (ACE inhibitor / angiotensin receptor blockers, β-blockers, calcium channel 
blockers or diuretics) (106). 
 
While initial evidence being limited, there is still hope for pharmacogenetic studies to expand in 
sample sizes, potentially identify genetic variants with contrasting associations and unique effects to 
different classes of antihypertensive drugs. There are still many barriers before being able to reach 
clinical application, which would also need to require the consideration of cost-effectiveness, 
particularly in the presence of only marginal gains. 
 
Summary   
In light of the largest cardiovascular GWAS to date, this review considered whether the knowledge of 
hypertension genomics has made an impact on clinical practice, and how it may do so in the future. 
Of the numerous loci and genes implicated in the pathophysiology of hypertension, UMOD has shown 
promise as a new pharmacological target, and there is a strong enrichment of targets within the TGF-
β pathway. In the future, there may be a role for combining GWAS of other comorbidities or 
cardiovascular endpoints to identify targets that may have a dual effect, where CPS1, MTNR1B and 
ABO may be the best options highlighted. The development of large DNA biobanks with dense 
phenotypic information would also allow future studies in the form of PheWAS (phenome-wide 
association studies), where well-curated electronic health records would allow investigators to use a 
variety of input functions such as single/multiple SNPs, drug exposure or predicted gene expression 
to probe broader phenotypes (107). GxE studies may also be important in this aspect, with CASP4 
appearing as an interesting candidate gene for salt-sensitivity. Pharmacogenetic and genetic risk score 
studies have also reveal some exciting mechanistical insights, but clinical application currently remains 
a distant prospect. With an expansion in the sample sizes of studies, the combination of multiple 
genetic signals may be sufficient to achieve clinical significance in the future. Should the technological 





SNP Gene (or nearest) Associated trait Expression 
Arteries Renal cortex Adrenal Highest 
expressing 
tissues 
rs12454712 Intronic BCL2 BCL2, Apoptosis 
Regulator 
SBP (4) + T2DM 
(19) 
Low Low Very low  Lymphocytes  








rs7412 Missense APOE Apolipoprotein E PP (4) + LDL (21) + 
HDL (22) 
Moderate High  Very high Liver, 
adrenals 
rs79598313 Intronic KDF1 Keratinocyte 
Differentiation Factor 1 
SBP (4) + LDL (23) Minimal / 
undetectable 
Low Very low  Skin, 
oesophagus, 
thyroid 
rs1047891 Missense CPS1 Carbamoyl-Phosphate 
Synthase 1 
SBP (4) + HDL (24) Very low  Low Very low  Liver 
 
Table 1: Overlapping signals between blood pressure and other cardiovascular risk-factor GWAS.  
SBP – systolic blood pressure; PP – pulse pressure; T2DM – Type II diabetes mellitus; LDL – low density lipoprotein cholesterol; HDL – high density lipoprotein 
cholesterol. 
Where multiple studies have identified the genome-wide association, the earlier study is quoted. 
Expression based on GTEx data, cut-off mean TPM (tags per million) set at minimal/undetectable <0.2; very low 0.2 to 2, low 2 to 20, moderate 20 to 100, 
high 100 to 1000 and very high >1000 for easier comparison. 
  
Traits Number of 
studies 
Approximate size of largest studies 




  51 * 40000 cases, 160000 controls (36) Broad range - European, South Asian 
and East Asian ancestries 




Myocardial infarction, coronary 
artery disease (combined 
endpoint) 
9 75000 cases, 260000 controls ((37) - CAD), 
38000 cases, 125000 controls ((38) - MI) 
Predominantly European, some other 
ancestries in largest studies 
Stroke Stroke, ischaemic stroke, small 
vessel or large artery stroke 




Chronic kidney disease, ESRF 
(small samples), Creatinine and 
kidney function decline 
8 90000 individuals (40) Predominantly European 
Heart failure   2 22000 individuals (41) Predominantly European 
 
Table 2: Heterogeneity of classification, number/size of studies and populations/ancestries of cardiovascular GWAS 
Summary characteristics of GWAS studies as derived from GWAS catalog (https://www.ebi.ac.uk/gwas/) 
* Not including GWAS studies on “glycosylated haemoglobin A1c” 
 
  
SNP Gene (or nearest) Associated trait Expression 
Arteries Renal cortex Adrenal Highest 
expressing 
tissues 
rs7412 Missense APOE Apolipoprotein E PP (4) + CAD (37) Moderate Very high Very high Liver, 
adrenals 




EDNRA Endothelin Receptor 
Type A 






Intronic SWAP70 SWAP Switching B-Cell 
Complex Subunit 70 
DBP (4) + CAD (38)  Moderate Low Low Adipose, 
tibial nerve, 
spleen 
rs9472135 Intergenic VEGFA Vascular Endothelial 
Growth Factor A 
DBP (4) + eGFR (43) Moderate Moderate Moderate Thyroid 
rs1047891 Missense CPS1 Carbamoyl-Phosphate 
Synthase 1 
SBP (4) + eGFR (40) Very low  Low Very low  Liver 
 
Table 3: Overlapping signals between blood pressure and cardiovascular endpoint GWAS.  
* denotes SNPs which are in high LD across GWAS (and the SNPs are listed in order of blood pressure variant first); SBP – systolic blood pressure; DBP – 
diastolic blood pressure; PP – pulse pressure; CAD – composite outcome of coronary artery disease including myocardial infarction, percutaneous transluminal 
coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease; eGFR – estimated glomerular filtration rate. 
Where multiple studies have identified the genome-wide association, the earlier study is quoted. 
Expression based on GTEx data, cut-off mean TPM (tags per million) set at minimal/undetectable <0.2; very low 0.2 to 2, low 2 to 20, moderate 20 to 100, 
high 100 to 1000 and very high >1000 for easier comparison. 
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